Concurrent Chemoradiotherapy with Pirarubicin and 5-fluorouracil for Resectable Oral and Maxillary Carcinoma

References

• Licitra L, Grandi C, Guzzo M, Mariani L, Lo Vullo S, Valvo F, et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 2003; 21: 327–33.
   PubMed Web of Science ®Google Scholar
• Olmi P, Crispino S, Fallai C, Toni V, Rossi F, Bolner A, et al. Locoregionally advanced carcinoma of the oro-pharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radio-therapy and chemotherapy - a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003; 55: 78–92.
   Google Scholar
• Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of con-current chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92–8.
   Google Scholar
• Ita M, Okafuji M, Fukuda K, Mitsuoka K, Hanakita T, Hayatsu Y. Concurrent chemoradiotherapy with new platinum compound nedaplatin in oral cancer. Oral Oncol 2003; 39: 144–9.
   Google Scholar
• Umezawa H, Takahashi Y, Kinoshita M, Naganawa H, Masuda T, Ishizuka M, et al. Tetrahydropyranyl deri-vatives of daunomycin and adriamycin. J Antibiot 1979; 32: 1082–4.
   PubMed Web of Science ®Google Scholar
• Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. 4'-0-tetrahydropyranyladriamycin as a potential new anti-tumor agent. Cancer Res 1982; 42: 1462–7.
   PubMed Web of Science ®Google Scholar
• Majima H, Ohta K. Clinical studies of (2"R)-4'-0-tetrahydropyranyl adriamycin (THP). Biomed Pharmac-other 1987; 41: 237–43.
   Google Scholar
• Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol 1990; 13 Suppl 1: 15–9.
   Google Scholar
• Munck JN, Fourcade A, Bennoun M, Tapiero H. Relationship between the intracellular level and growth inhibition of a new anthracycline 4'0-tetrahydropyra-nyl-Adriamycin in Friend leukemia cell variants. Leuk Res 1985; 9: 289–96.
   Google Scholar
• Okamura K, Ono Y, Kinukawa T, Matsuura O, Yamada S, Ando T, et al. Randomized study of single early instillation of (2"R)-4'-0-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 2002; 94: 2363–8.
   PubMed Web of Science ®Google Scholar
• Akaza H, Niijima T, Hisamatsu T, Fujigaki M. Com-parative investigation on use of (2"R)-4'-0-tetrahydro-pyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. Urology 1988; 32: 141–5.
   Google Scholar
• Mathe G, Umezawa H, Oka S, Misset JL, Brienza S, de Vassal F, et al. An oriented phase II trial of THP-adriamycin in breast carcinoma. Biomed Pharmacother 1986; 40: 376–9.
   Google Scholar
• Chevallier B, Mignot L, Delozier T, Morvan F, Ferme C, Herait P. Phase II study of tetrahydropyranyl adriamycin (pirarubicin) in elderly patients with ad-vanced breast cancer. Am J Clin Oncol 1992; 15: 395–8.
   Google Scholar
• Samonigg H, Stoger H, Bauernhofer T, Schmid M, Kasparek AK, Kuss I, et al. Combination therapy of 4'-0-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose folinic acid in patients with advanced breast cancer: a phase I-II study (preliminary results). Am J Clin Oncol 1990; 13 Suppl 1: S44–7.
   Google Scholar
• Noguchi M, Murata R, Sagoh T, Yamamoto M, Ueda H, Kinoshita K, et al. Intraarterial chemotherapy combined with radiation therapy for advanced cancer of the uterine cervix. Jpn J Cancer Chemother 1998; 25: 1314–7.
   Google Scholar
• Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset JL, et al. Chemotherapy of advanced ovarian cancer with 4'-0-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 1990; 8: 705–14.
   Google Scholar
• Kato T, Nishimura H, Umezu J, Takeuchi S, Kanazawa K, Inoue H, et al. Phase II study of 4'-0-tetrahydropyr-anyl-adriamycin (THP-ADM) in patients with gyneco-logical cancer. Jpn J Cancer Chemother 1985; 12: 1962–7.
   Google Scholar
• Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP. Phase II trial of 4'-0-tetrahy-dropyranyladriamycin (pirarubicin) in head and neck carcinoma. Cancer 1992; 70: 1591–7.
   PubMed Web of Science ®Google Scholar
• Honda T, Ohyama W, Sonoda T, Uchida K, Hirokawa T, Takada K, et al. Intraarterial infusion of 4'-0-tetrahydropyranyl-adriamycin for head and neck tu-mors. Jpn J Antibiot 1984; 37: 959–65.
   Google Scholar
• Ogawa A, Yamashita K. A study on the correlation between the concentration of antitumor agent and the clinical effect. An experience with THP-ADM. Jpn J Cancer Chemother 1985; 12: 303–8.
   Google Scholar
• Kunimoto S, Miura K, Takahashi Y, Takeuchi T, Umezawa H. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-0-tetrahydropyranyla-driamycin. J Antibiot 1983; 36: 312–7.
   Google Scholar
• Kunimoto S, Miura K, Umezawa K, Xu CZ, Masuda T, Takeuchi T, et al. Cellular uptake and efflux and cytostatic activity of 4'-0-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines. J Antibiot 1984; 37: 1697–702.
   Google Scholar
• Fujii M, Ohno Y, Kanzaki J. Effects of anticancer drugs and combination effects of anthracyclines on the hypoxic cells of head and neck cancer. Jpn J Cancer Chemother 1995; 22: 647–52.
   Google Scholar
• Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981; 41: 73–81.
   Google Scholar
• Takahashi T, Mitsuhashi N, Sakurai H, Murata O, Kitamoto Y, Matsumoto H, et al. Thermal enhancement of pirarubicin (THP-adriamycin) by mild hyperthermia in vitro. Int J Hyperthermia 1997; 13: 317–24.
   PubMed Web of Science ®Google Scholar
• Koutcher JA, Alfieri AA, Thaler H, Matei C, Martin DS. Radiation enhancement by biochemical modulation and 5-fluorouracil. Int J Radiat Oncol Biol Phys 1997; 39: 1145–52.
   Google Scholar
• Nagasawa M, Ishii S, Kariya Y, Itoh O, Yamamoto H, Kawaharajo K, et al. In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines. Jpn J Cancer Chemother 1990; 17: 633–8.
   Google Scholar
• Marchiset-Leca D, Leca FR, Galeani A, Noble A, Catalin J. Pharmacokinetics and metabolism of pirar-ubicin in humans: correlation with pharmacodynamics. Cancer Chemother Pharmacol 1995; 36: 239–43.
   Google Scholar
• Cameron DA, Gabra H, Leonard RC. Continuous 5-fluorouracil in the treatment of breast cancer. Br J Cancer 1994; 70: 120–4.
   PubMed Web of Science ®Google Scholar
• Okutomi T, Kato Y, Ichihara H, Hyodo I, Fujitsuka H, Yasuda S, et al. Clinical effects of adjuvant therapy using Z-100 (Ancer 20 injection) for oral cancer - prevention of stomatitis and hematopoietic impairment. Jpn J Cancer Chemother 2000; 27: 65–71.
   Google Scholar
• Dantchev D, Paintrand M, Hayat M, Bourut C, Mathe G. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 1979; 32: 1085–6.
   Google Scholar
• Hicks WL Jr, North JH Jr, Loree TR, Maamoun S, Mullins A, Orner JB, et al. Surgery as a single modality therapy for squamous cell carcinoma of the oral tongue. Am J Otolaryngol 1998; 19: 24–8.
   Google Scholar